相关实验视频

Updated: Jun 29, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

宏环抑制剂BI-4020与EGFR激酶结合的结构分析

Tyler S Beyett^1,2, Jaimin K Rana^1,2, Ilse K Schaeffner^1,2

¹Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA, 450 Brookline Avenue, LC4313.

|March 24, 2024

概括

一种新的宏环抑制剂BI-4020显示出对抗药物耐药突变EGFR的高强度和选择性,为向非小细胞肺癌治疗提供了一个有希望的途径.

科学领域:

药用化学医学化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

非小细胞肺癌 (NSCLC) 往往会对向治疗产生耐药性.
表皮生长因子受体 (EGFR) 的突变,如T790M和C797S,是耐药性的关键驱动因素.
需要新的抑制剂来克服这些抵抗机制.

研究的目的:

阐明新型宏环抑制剂BI-4020的选择性和强度的分子基础.
了解其与野生型和突变EGFR变体的相互作用.
为开发下一代EGFR抑制剂提供见解.

主要方法:

进行生物化学活性测试以确定抑制剂的强度.
使用X射线结晶学分析BI-4020与EGFR激酶域的结构相互作用.
与Osimertinib等现有抑制剂进行了比较分析.

主要成果:

BI-4020对耐药EGFR变种 (L858R/T790M和L858R/T790M/C797S) 显示出独特的功效.
结构分析显示,BI-4020与EGFR链区域和T790M突变相互作用,有助于选择性.
抑制剂的受约束的宏循环和额外的键增强了对活性和非活性EGFR构造的效力.

结论:

BI-4020是一种高度强效和选择性的EGFR突变的可逆抑制剂.
它独特的结合模式为针对NSCLC的向疗法的结构灵感设计提供了基础.
这些发现支持开发针对耐药癌症的新型药物瘤学策略.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...